Targeting PI3K in cancer: mechanisms and advances in clinical trials
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Authors
Keywords
PI3K, mTOR, Cancer, Target therapy
Journal
Molecular Cancer
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-19
DOI
10.1186/s12943-019-0954-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long non-coding RNA-422 acts as a tumor suppressor in colorectal cancer
- (2018) Qianwen Shao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p
- (2018) Shuqin Li et al. BIOMEDICINE & PHARMACOTHERAPY
- Long non-coding RNA CRNDE promotes heptaocellular carcinoma cell proliferation by regulating PI3K/Akt /β-catenin signaling
- (2018) Qiling Tang et al. BIOMEDICINE & PHARMACOTHERAPY
- Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
- (2018) Sarika Jain et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
- (2018) R D Kim et al. BRITISH JOURNAL OF CANCER
- Crosstalk between the Notch signaling pathway and long non-coding RNAs
- (2018) Andreas Reicher et al. CANCER LETTERS
- Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma
- (2018) Hideki Makinoshima et al. CANCER RESEARCH
- Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers
- (2018) Filip Mundt et al. CANCER RESEARCH
- Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer
- (2018) Kenji Tamura et al. CANCER SCIENCE
- LncRNA GAS5 Represses Osteosarcoma Cells Growth and Metastasis via Sponging MiR-203a
- (2018) Yang Wang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3 K/Akt pathway
- (2018) Xiaolan Yu et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a
- (2018) Chuanyao Cheng et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- MicroRNA-103 confers the resistance to long-treatment of adriamycin to human leukemia cells by regulation of COP1
- (2018) Lin Wan et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- Linc00659, a long noncoding RNA, acts as novel oncogene in regulating cancer cell growth in colorectal cancer
- (2018) Kuo-Wang Tsai et al. Molecular Cancer
- Long noncoding RNA HULC accelerates liver cancer by inhibiting PTEN via autophagy cooperation to miR15a
- (2018) Xiaoru Xin et al. Molecular Cancer
- PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy
- (2018) Nahal Haddadi et al. Molecular Cancer
- The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma
- (2018) Jin-lan Huang et al. Molecular Cancer
- Long Noncoding RNA PlncRNA-1 Promotes Colorectal Cancer Cell Progression by Regulating the PI3K/Akt Signaling Pathway
- (2018) Wei Song et al. ONCOLOGY RESEARCH
- Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer
- (2018) Myung Woul Han et al. ORAL ONCOLOGY
- Long noncoding RNA RP4 functions as a competing endogenous RNA through miR-7-5p sponge activity in colorectal cancer
- (2018) Mu-Lin Liu et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Prostate Power Play: Does Pik3ca Accelerate Pten -Deficient Cancer Progression?
- (2018) Joanna Triscott et al. Cancer Discovery
- Long Noncoding RNA LINC003121 Inhibits Proliferation and Invasion of Thyroid Cancer Cells by Suppression of the Phosphatidylinositol-3-Kinase (PI3K)/Akt Signaling Pathway
- (2018) Xiang Min et al. MEDICAL SCIENCE MONITOR
- PTEN: Tumor Suppressor and Metabolic Regulator
- (2018) Chien-Yu Chen et al. Frontiers in Endocrinology
- Biological Function and Mechanism of Long Noncoding RNAs Nuclear-Enriched Abundant Transcript 1 in Development of Cervical Cancer
- (2018) Cai-Ping Mao et al. CHINESE MEDICAL JOURNAL
- Geniposide suppresses growth, migration and invasion of MKN45 cells by down-regulation of lncRNA HULC
- (2018) Ji Ma et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Knockdown of long noncoding RNA urothelial carcinoma-associated 1 inhibits cell viability, migration, and invasion by regulating microRNA-182 in gastric carcinoma
- (2018) Lei Qin et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Mechanisms behind resistance to PI3K Inhibitor treatment induced by the PIM kinase
- (2018) Jin H. Song et al. MOLECULAR CANCER THERAPEUTICS
- ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition
- (2018) Kara M. Ruicci et al. ORAL ONCOLOGY
- Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling
- (2018) Muhammad Waqas Usman et al. Cell Death & Disease
- Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression
- (2018) Yuan Jiang et al. Nature Communications
- Knockdown of lncRNA-H19 inhibits cell viability, migration and invasion while promotes apoptosis via microRNA-143/RUNX2 axis in retinoblastoma
- (2018) Defeng Qi et al. BIOMEDICINE & PHARMACOTHERAPY
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- MEG3 affects the progression and chemoresistance of T‐cell lymphoblastic lymphoma by suppressing epithelial‐mesenchymal transition via the PI3K/mTOR pathway
- (2018) Rui Deng et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway
- (2018) Bing Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer
- (2018) Wei Jiang et al. Journal of Hematology & Oncology
- Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
- (2018) Guojun Wang et al. MEDICAL SCIENCE MONITOR
- Epigenetic regulation of HOTAIR in advanced chronic myeloid leukemia
- (2018) Ziye Li et al. Cancer Management and Research
- Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
- (2017) Christophe Massard et al. EUROPEAN JOURNAL OF CANCER
- A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer
- (2017) Jean-Charles Soria et al. EUROPEAN JOURNAL OF CANCER
- Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
- (2017) Sibylle Loibl et al. EUROPEAN JOURNAL OF CANCER
- Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
- (2017) Andrew J. Armstrong et al. EUROPEAN JOURNAL OF CANCER
- An Oncolytic Adenovirus Expressing SNORD44 and GAS5 Exhibits Antitumor Effect in Colorectal Cancer Cells
- (2017) Sujing Yuan et al. HUMAN GENE THERAPY
- A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
- (2017) Lillian M. Smyth et al. INVESTIGATIONAL NEW DRUGS
- Knockdown of long non-coding RNA ANRIL inhibits proliferation, migration, and invasion but promotes apoptosis of human glioma cells by upregulation of miR-34a
- (2017) Xuechao Dong et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Knockdown of long non-coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR-195
- (2017) Dingli Liu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Knockdown of lncRNA HULC inhibits proliferation, migration, invasion, and promotes apoptosis by sponging miR-122 in osteosarcoma
- (2017) Daliang Kong et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway
- (2017) Yaling Li et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- JAK2-binding long noncoding RNA promotes breast cancer brain metastasis
- (2017) Shouyu Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
- (2017) Martin Dreyling et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets
- (2017) Marcel Klingenberg et al. JOURNAL OF HEPATOLOGY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- The crosstalk between long non-coding RNAs and PI3K in cancer
- (2017) Leonidas Benetatos et al. MEDICAL ONCOLOGY
- Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway
- (2017) Bing Liu et al. MOLECULAR CARCINOGENESIS
- Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells
- (2017) Mara Compagno et al. NATURE
- A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors
- (2017) Stephen Leong et al. ONCOLOGIST
- Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
- (2017) Ramon Salazar et al. ONCOLOGIST
- Long non-coding RNA MEG3 inhibits cell growth of gliomas by targeting miR-93 and inactivating PI3K/AKT pathway
- (2017) Ling Zhang et al. ONCOLOGY REPORTS
- A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
- (2017) Zev A. Wainberg et al. Targeted Oncology
- A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
- (2017) Trisha M. Wise-Draper et al. Targeted Oncology
- Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway
- (2017) Hui Shi et al. TUMOR BIOLOGY
- Long non-coding RNA Myd88 promotes growth and metastasis in hepatocellular carcinoma via regulating Myd88 expression through H3K27 modification
- (2017) Xiaoliang Xu et al. Cell Death & Disease
- LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma
- (2017) Nan Yang et al. Cell Death & Disease
- Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer
- (2017) Bi-Dar Wang et al. Nature Communications
- Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2017) Dejan Juric et al. Cancer Discovery
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer
- (2017) Robin M.J.M. van Geel et al. Cancer Discovery
- FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway
- (2017) Keigo Okada et al. Oncotarget
- Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
- (2017) Sonali M Smith et al. Lancet Haematology
- Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
- (2016) Brittany Knick Ragon et al. AMERICAN JOURNAL OF HEMATOLOGY
- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- (2016) A. Patnaik et al. ANNALS OF ONCOLOGY
- Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors
- (2016) YI-LONG WU et al. ANTICANCER RESEARCH
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer
- (2016) Didier Meseure et al. BRITISH JOURNAL OF CANCER
- A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
- (2016) Rana R. McKay et al. CANCER
- A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
- (2016) Vicky Makker et al. CANCER
- A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
- (2016) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110
- (2016) Y. Nakanishi et al. CANCER RESEARCH
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer
- (2016) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
- (2016) Vivek Asati et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
- (2016) Josep María del Campo et al. GYNECOLOGIC ONCOLOGY
- The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells
- (2016) Haiying Wang et al. Hematology
- Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer
- (2016) Noboru Yamamoto et al. INVESTIGATIONAL NEW DRUGS
- Long non-coding RNA Malat1 promotes neurite outgrowth through activation of ERK/MAPK signalling pathway in N2a cells
- (2016) Lei Chen et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer
- (2016) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2016) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
- (2016) V M Patel et al. LEUKEMIA
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease
- (2016) Helma Freitag et al. NEUROENDOCRINOLOGY
- Long non-coding RNA ATB promotes growth and epithelial-mesenchymal transition and predicts poor prognosis in human prostate carcinoma
- (2016) SONG XU et al. ONCOLOGY REPORTS
- Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
- (2016) XIAOYU YANG et al. Oncology Letters
- Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
- (2016) X. Le et al. Cancer Discovery
- Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles
- (2016) E. Kim et al. Cancer Discovery
- RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma
- (2016) Lucas Goedert et al. Oncotarget
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
- (2015) David M. Hyman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
- (2015) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
- (2015) Autumn J. McRee et al. INVESTIGATIONAL NEW DRUGS
- The PI3K/AKT Pathway and Renal Cell Carcinoma
- (2015) Huifang Guo et al. Journal of Genetics and Genomics
- Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3CβD1067V kinase domain mutation
- (2015) E Pazarentzos et al. ONCOGENE
- Targeting PI3 kinase in cancer
- (2015) Todd M. Bauer et al. PHARMACOLOGY & THERAPEUTICS
- Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells
- (2015) Kiren Yacqub-Usman et al. PROSTATE
- PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer
- (2015) Libing Xiang et al. Scientific Reports
- PI3K/AKT signaling pathway and cancer: an updated review
- (2014) Miriam Martini et al. ANNALS OF MEDICINE
- An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial–mesenchymal transition and cancer stem cell expansion in human breast cancer cells
- (2014) Lin Yang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells
- (2014) S. Dong et al. BLOOD
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
- (2014) I. W. Flinn et al. BLOOD
- A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2014) B. S. Kahl et al. BLOOD
- Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy
- (2014) Mark R. Pickard et al. BREAST CANCER RESEARCH AND TREATMENT
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET
- (2014) Jian-Ya Zhou et al. CANCER LETTERS
- Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
- (2014) Yuichi Ando et al. CANCER SCIENCE
- Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function
- (2014) Antonella Papa et al. CELL
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
- (2014) C. Saura et al. CLINICAL CANCER RESEARCH
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Idelalisib: First Global Approval
- (2014) Anthony Markham DRUGS
- 382 Phase Ib study of oral dual-PI3K/mTOR inhibitor GDC-0980 in combination with capecitabine and mFOLFOX6 + bevacizumab in patients with advanced solid tumors and colorectal cancer
- (2014) L. Rosen et al. EUROPEAN JOURNAL OF CANCER
- Dual Inhibition of Phosphatidylinositol 3′-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach for Mucinous Adenocarcinoma of the Ovary
- (2014) Akiko Kudoh et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
- (2014) Carolyn D. Britten et al. INVESTIGATIONAL NEW DRUGS
- Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
- (2014) Jordi Rodon et al. INVESTIGATIONAL NEW DRUGS
- The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer
- (2014) Peixin Dong et al. Journal of Translational Medicine
- GAS5 long non-coding RNA in malignant pleural mesothelioma
- (2014) Arun Renganathan et al. Molecular Cancer
- Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
- (2014) C. Fritsch et al. MOLECULAR CANCER THERAPEUTICS
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma
- (2014) Qiang Xie et al. NEUROPATHOLOGY
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway
- (2014) Yongqiang Dong et al. TUMOR BIOLOGY
- Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
- (2013) Klaus Okkenhaug Annual Review of Immunology
- NVP-BEZ235, Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor, Prominently Enhances Radiosensitivity of Prostate Cancer Cell Line PC-3
- (2013) Wenjie Zhu et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
- (2013) A. Herzog et al. CLINICAL CANCER RESEARCH
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells
- (2013) Erika Martinelli et al. INTERNATIONAL JOURNAL OF CANCER
- RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
- (2013) Violeta Serra et al. JOURNAL OF CLINICAL INVESTIGATION
- Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
- (2013) Y. Wang et al. MOLECULAR CANCER THERAPEUTICS
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase
- (2013) Hashem A. Dbouk et al. PLoS One
- Genetic heterogeneity of diffuse large B-cell lymphoma
- (2013) Jenny Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in PIK3CA-Mutant Breast Cancer
- (2013) M. Elkabets et al. Science Translational Medicine
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
- (2012) Adrian Britschgi et al. CANCER CELL
- Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer
- (2012) Timothy R. Donahue et al. CLINICAL CANCER RESEARCH
- Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells
- (2012) Chen Yang et al. GENE
- An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
- (2012) Kathryn M. Kinross et al. JOURNAL OF CLINICAL INVESTIGATION
- β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
- (2012) Stephan P Tenbaum et al. NATURE MEDICINE
- Conditional activation of Pik3ca H1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations
- (2012) W Yuan et al. ONCOGENE
- G Protein-Coupled Receptor-Mediated Activation of p110 by G Is Required for Cellular Transformation and Invasiveness
- (2012) H. A. Dbouk et al. Science Signaling
- PTEN Level in Tumor Suppression: How Much Is Too Little?
- (2011) A. Carracedo et al. CANCER RESEARCH
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
- (2011) J. Yuan et al. MOLECULAR CANCER THERAPEUTICS
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
- (2011) Markus K Muellner et al. Nature Chemical Biology
- Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms
- (2011) Pixu Liu et al. NATURE MEDICINE
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
- (2011) N. Ilic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors
- (2010) K. A. Edgar et al. CANCER RESEARCH
- Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
- (2010) P. Workman et al. CANCER RESEARCH
- Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function
- (2010) Wai-Ping Fung-Leung CELLULAR SIGNALLING
- Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
- (2010) S. A. Aziz et al. CLINICAL CANCER RESEARCH
- Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
- (2010) C. O'Brien et al. CLINICAL CANCER RESEARCH
- The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
- (2010) D. C. Cho et al. CLINICAL CANCER RESEARCH
- The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
- (2010) P M Bhende et al. LEUKEMIA
- Diverse somatic mutation patterns and pathway alterations in human cancers
- (2010) Zhengyan Kan et al. NATURE
- Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma
- (2009) S. A. Aziz et al. CLINICAL CANCER RESEARCH
- Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
- (2009) R. Marone et al. MOLECULAR CANCER RESEARCH
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
- (2009) F. I. Raynaud et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis
- (2008) Christian Stockmann et al. NATURE
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
- (2008) Shidong Jia et al. NATURE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
- Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
- (2008) L. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now